Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cellectar Biosciences Inc

CLRB ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$2.60

▲ +4.84%

Market Cap $24.58M · Vol 9.15K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$24.58M

Micro Cap

Div Yield

N/A

EPS Growth

+76.34%

YoY

RSI (14)

60.98

Momentum

Beta

0.57

vs Market

52W High

$6.52

60.12% below

52W Low

$2.20

18.18% above

Volume

9.15K

Avg 14.25K

P/B

1.56

Price-to-book

ROE

N/A

Return on equity

Free Float

97.93%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cellectar Biosciences Inc (CLRB) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CLRB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.17%

-1.14%

-18.75%

-21.45%

YTD

-11.86%

-41.18%

-95.05%

-99.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-21,791,040.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-107.74% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.56
P/FCF	N/A
EPS Growth	+76.34%
Outstanding Shares	9.45M

Technical Indicators

50-Day SMA	$2.56
200-Day SMA	$2.99
RSI (14)	60.98
Beta	0.57
52-Week High	$6.52
52-Week Low	$2.20

Volume Today	9.15K
Avg Daily Volume (30D)	14.25K
Relative Volume	0.64x
Volatility (10D)	45.66
Volatility (30D)	41.71
Free Float	97.93%

Analyst Consensus

BUY

Current Price $2.60

Mean Target $10.33

52W Low$2.20 52W High$6.52

Current

Target

$2.20 $6.52

Current Analyst target

+297.44% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SNWCK2

ISINUS15117F8804

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 15, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.